Glepaglutide 20.0 mg/mL
ZP1848-20110
Phase 3 small_molecule active
Quick answer
Glepaglutide 20.0 mg/mL for Short bowel syndrome is a Phase 3 program (small_molecule) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Zealand Pharma A/S
- Indication
- Short bowel syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active